Combination of Radiotherapy and Immunotherapy for Unresectable Stage III Non-small Cell Lung Cancer: Clinical Progress Advances and Future Directions.
Stage III non-small cell lung cancer (NSCLC) accounts for approximately 30% of newly diagnosed NSCLC cases, and the vast majority of these patients present with unresectable disease. Its unresectable nature makes definitive chemoradiotherapy the cornerstone of treatment. In recent years, with immune...
| Published in: | Chinese Journal of Lung Cancer Vol. 28; no. 11; pp. 866 - 875 |
|---|---|
| Main Authors: | , , , |
| Format: | review tables/charts Journal Article |
| Published: |
Chinese Journal of Lung Cancer
Nov2025
|
| Online Access: | View this record in EBSCOhost |